United Therapeutics Corp (NAS:UTHR)
$ 360.87 -2.78 (-0.76%) Market Cap: 16.11 Bil Enterprise Value: 13.18 Bil PE Ratio: 15.85 PB Ratio: 2.64 GF Score: 86/100

United Therapeutics Corp at Wedbush PacGrow Healthcare Conference Transcript

Aug 13, 2019 / 02:20PM GMT
Release Date Price: $80.16 (-1.27%)
Vasiliana Vireen Moussatos
Wedbush Securities Inc., Research Division - MD of Equity Research

Hello. Thank you for attending the Wedbush Healthcare Conference. I'm Liana Moussatos, one of the senior analysts. It's our great pleasure to have a fireside chat, Q&A with the CEO and CFO of United Therapeutics and get an update; the CEO, Dr. Martine Rothblatt and the CFO, James Edgemond.

Dr. Rothblatt has led the company to develop breakthrough treatments in delivery systems for PAH and delivered early profitability, top and bottom line growth and significant free cash flow, which makes United Therapeutics unusual and -- especially in my coverage.

Questions & Answers

Vasiliana Vireen Moussatos
Wedbush Securities Inc., Research Division - MD of Equity Research

Dr. Rothblatt, on the Q2 call, you projected tripling in revenues, but near term analysts' projections imply that top and bottom line growth may be bumpy for the next couple of years as the company transitions dependence on generation 1 delivery for Remodulin and Tyvaso to generation 2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot